Relevance of dopamine D2/neurotensin NTS1 and NMDA/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders

Current Medicinal Chemistry

Volumn 19, Issue 3, 2012, Pages 304-316

  Tanganelli, S ^a   Antonelli, T ^a,b   Tomasini, M C ^a,b   Beggiato, S ^a,b   Fuxe, K ^c   Ferraro, L ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRET Foundation   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic drugs; Cerebral ischemia; Dopamine; Glutamate; Microdialysis; Neurotensin analogues; NTS1 receptor; Nucleus accumbens; Receptor heteromers; SR48692; Structure activity relationship

Indexed keywords

CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; MECLINERTANT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR ANTAGONIST; NEUROTENSIN RECEPTOR SUBTYPE 1; NEUROTENSIN RECEPTOR SUBTYPE 2; NEUROTENSIN RECEPTOR SUBTYPE 4; SORTILIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; ENZYME ACTIVITY; GABAERGIC TRANSMISSION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SCHIZOPHRENIA; WILD TYPE;

EID: 84857724379     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803414268     Document Type: Article

References (168)

1. Fuxe, K.; Agnati, L.F.; Benfenati, F.; Cimmino, M.; Algeri, S.; Hökfelt T.; Mutt, V. Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: Evidence for increased affinity and reduction in the number of binding sites. Acta Physiol. Scand., 1981, 113, 567-569. (Pubitemid 12183362)
2. Agnati, L.F.; Fuxe, K.; Zoli, M.; Rondanini C.; Ogren, S.O. New vistas on synaptic plasticity: The receptor mosaic hypothesis of the engram. Med. Biol., 1982, 60, 183-190. (Pubitemid 13253962)
3. Fuxe, K.; Agnati, L.F.; Benfenati, F.; Celani, M.; Zini, I.; Zoli M.; Mutt, V. Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. Neural Transm. Suppl., 1983, 18, 165-179.
4. Carraway, R.; Leeman, S.E.; The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol. Chem., 1973, 248, 6854-61.
5. Kitabgi, P.; Carrawa, R.; Leeman, S.E. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J. Biol. Chem., 1976, 251(22),7053-7058.
6. Hammer, R.A.; Leeman, S.E.; Carraway, R.; Williams, R.H. Isolation of human intestinal neurotensin. J. Biol. Chem., 1980, 255(6), 2476-2480. (Pubitemid 10036048)
7. Kitabgi, P. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides, 2006, 27, 2515-2522. (Pubitemid 44402791)
8. Ortego, J.; Coca-Prados, M. Molecular characterization and differential gene induction of the neuroendocrine-specific genes neurotensin, neurotensin receptor, PC1, PC2, and 7B2 in the human ocular ciliary epithelium. J. Neurochem., 1997, 69(5), 1829-1839. (Pubitemid 27452727)
9. Villeneuve, P.; Lafortune, L.; Seidah, N.G.; Kitabgi, P.; Beaudet, A. Immunohistochemical evidence for the involvement of protein convertases 5A and 2 in the processing of pro-neurotensin in rat brain. J. Comp. Neurol., 2000, 424(3), 461-75. (Pubitemid 30670444)
10. Kitabgi, P. Neurotensin and Neuromedin N Are Differentially Processed from a Common Precursor by Prohormone Convertases in Tissues and Cell Lines. Cellular. Peptide Hormone Synthesis and Secretory Pathways, J.F. Rehfeld and J.R. Bundgaard, Editors. 2010, Springer Berlin/ Heidelberg. p. 63-84.
11. Kitabgi P. Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases. Peptides, 2006, 27(10), 2508-14. (Pubitemid 44402790)
12. Checler, F.; Vincent, J.P.; Kitabgi, P. Neuromedin N: High affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases. Eur. J. Pharmacol., 1986, 126(3), 239-244. (Pubitemid 16016554)
13. Kitabgi, P.; De Nadai, F.; Rovère, C.; Bidard, J.N. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. Ann. N.Y. Acad. Sci., 1992, 668, 30-42. (Pubitemid 23025844)
14. Vincent, B.; Jiracek, J.; Noble, F.; Loog, M.; Roques, B.; Dive, V.; Vincent, J.P.; Checler, F. Contribution of endopeptidase 3.4.24.15 to central neurotensin inactivation. Eur. J. Pharmacol., 1997, 334(1), 49-53. (Pubitemid 27417808)
15. Kitabgi, P.; Carraway, R.; Van Rietschoten, J.; Granier, C.; Morgat, J.L.; Menez, A.; Leeman, S.; Freychet, P. Neurotensin: Specific binding to synaptic membranes from rat brain. Proc. Natl. Acad. Sci., 1977, 74(5), 1846-1850. (Pubitemid 8123564)
16. Vincent, J.P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. TIPS, 1999, 20, 302-309. (Pubitemid 29301684)
17. Dobner, P.R. Multitasking with neurotensin in the central nervous system. Cell. Mol. Life Sci., 2005, 62,1946-63. (Pubitemid 41261842)
18. Mazella, J.; Zsürger, N.; Navarro, V.; Chabry, J.; Kaghad, M.; Caput, D.; Ferrara, P.; Vita, N.; Gully, D.; Maffrand, J.P.; Vincent, J.P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem., 1998, 273(41), 26273-26276. (Pubitemid 28471624)
19. Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron, 1990, 4(6), 847-854. (Pubitemid 20208510)
20. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Dumont, X.; Kaghad, M.; Gully, D.; Le Fur, G.; Ferrara, P.; Caput, D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett., 1993, 317 (1-2), 139-142. (Pubitemid 23043957)
21. Chalon, P.; Vita, N.; Kaghad, M.; Guillemot, M.; Bonnin, J.; Delpech, B.; Le Fur, G.; Ferrara, P.; Caput, D. Molecular cloning of a levocabastine- sensitive neurotensin binding site. FEBS Lett., 1996, 386, 91-94. (Pubitemid 26173063)
22. Vincent, J.P. Neurotensin receptors: Binding properties, transduction pathways, and structure. Cell. Mol. Neurobiol., 1995, 15, 501-512.
23. Yamada, M.; Watson, M.A.; Richelson, E. Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells. Mol. Pharmacol., 1994, 46, 470-476. (Pubitemid 24296680)
24. Poinot-Chazel, C.; Portier, M.; Bouaboula, M.; Vita, N.; Pecceu. F.; Gully, D.; Monroe, J.G.; Maffrand, J.P.; Le Fur, G.; Casellas, P. Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem. J., 1996, 320 ( Pt 1), 145-151. (Pubitemid 26400172)
25. Kitabgi, P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr. Opin. Drug. Discov. Devel., 2002, 5, 764-776. (Pubitemid 36253796)
26. Pelaprat D. Interactions between neurotensin receptors and G proteins. Peptides, 2006, 27, 2476-87. (Pubitemid 44425365)
27. Kitabgi, P. Functional domains of the subtype 1 neurotensin receptor (NTS1). Peptides, 2006, 27(10), 2461-8. (Pubitemid 44402789)
28. Kenakin, T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev., 1996, 48,413-63. (Pubitemid 126782561)
29. Kenakin, T. Ligand-selective receptor conformations revisited: The promise and the problem, Trends Pharmacol. Sci., 2003, 24(7), 346-54. (Pubitemid 37315526)
30. Hermans, E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors, Pharmacol. Ther., 2003, 99, 25-44. (Pubitemid 36694748)
31. Boudin, H.; Pélaprat, D.; Rostène, W.; Beaudet, A. Cellular distribution of neurotensin receptors in rat brain: Immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J. Comp. Neurol., 1996, 373, 76-89. (Pubitemid 26292120)
32. Alexander, M.J.; Leeman, S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J. Comp. Neurol., 1998, 402, 475-500. (Pubitemid 29001076)
33. Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. Neurotensin and dopamine interactions. Pharmacol. Rev., 2001, 53, 453-486. (Pubitemid 33136236)
34. Hetier, E.; Boireau, A.; Dubedat, P.; Blanchard, J.C. Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn-Schmiedeberg's Arch. Pharmacol., 1988, 337, 13-17. (Pubitemid 18061408)
35. Faggin, B.M.; Zubieta, J.K.; Rezvani, A.H.; Cubeddu, L.X. Neurotensininduced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J. Pharmacol. Exp. Ther., 1990, 252, 817-825. (Pubitemid 20101903)
36. Heaulme, M.; Leyris, R.; Le Fur, G.; Soubriè, P. Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal. Neuropharmacology, 1997, 36, 1447-1454.
37. Legault, M.; Congar, P.; Michel, F.J.; Trudeau, L.E. Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones. Neuroscience, 2002, 111, 177-187. (Pubitemid 34310460)
38. Seutin, V.; Massotte, L.; Dresse, A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology, 1989, 28, 949-954. (Pubitemid 19224338)
39. Jiang, Z.G.; Pessia, M.; North, R.A. Neurotensin excitation of rat ventral tegmental neurones. J. Physiol., 1994, 474, 119-129. (Pubitemid 24045637)
40. Werkman, T.R.; Kruse, C.G.; Nievelstein, H.; Long, S.K.; Wadman, W.J. Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the substantia nigra pars compacta and the ventral tegmental area. Neuroscience, 2000, 95, 417-423.
41. Hökfelt, T.; Everitt, B.J.; Theodorsson-Norheim, E.; Goldstein, M. Occurrence of neurotensin like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol., 1984, 222, 543-559. (Pubitemid 14198624)
42. Berger, B.; Gaspar, P.; Verney, C. Colocalization of neurotensin in the mesocortical dopaminergic system. Restricted regional and laminar distribution in rat, lack of colocalization in human. Ann. N. Y. Acad. Sci., 1992, 668, 307-310. (Pubitemid 23025866)
43. Betancur, C.; Canton, M.; Gully, D.; Vela, G.; Pélaprat, D.; Rostène, W. Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain. J Pharmacol Exp Ther., 1995 273(3), 1450-8.
44. Herve, D.; Tassin, J.P.; Studler, J.M.; Dana, C.; Kitabgi, P.; Vincent, J.P.; Glowinski, J.; Rostène, W. Dopaminergic control of 125 I-labeled neurotensin binding site density in corticolimbic structures of the rat brain. Proc. Natl. Acad. Sc., 1986, 83, 6203-6207. (Pubitemid 16000681)
45. Vita, N.; Oury-Donat, F.; Chalon, P.; Guillemot, M.; Kaghad, M.; Bachy, A.; Thurneyssen, O.; Garcia, S.; Poinot-Chazel, C.; Casellas, P.; Keane, P.; Le Fur, G.; Maffrand, J.P.; Soubrie, P.; Caput, D.; Ferrara, P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol., 1998, 360, 265-72. (Pubitemid 28529194)
46. Schotte, A.; Laduron, P.M. Different postnatal ontogeny of two [3H] neurotensin binding sites in rat brain. Brain Res., 1987, 408(1-2),326-8. (Pubitemid 17068454)
47. Zsurger, N.; Chabry, J.; Coquerel, A.; Vincent, J.P. Ontogenesis and binding properties of high-affinity neurotensin receptors in human brain. Brain Res., 1992, 586, 303-310.
48. Sarret, P.; Beaudet, A.; Vincent J.P. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J. Comp. Neurol., 1998, 394, 344-356. (Pubitemid 28208193)
49. Fassio, A.; Evans, G.; Grisshammer, R.; Bolam, J.P.; Mimmack, M.; Emson, P.C. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology, 2000, 39, 1430-1442. (Pubitemid 30249205)
50. Sarret, P.; Perron, A.; Stroh, T. Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J. Comp. Neurol., 2003, 461, 520-538. (Pubitemid 36629000)
51. St-Gelais, F.; Jomphe, C.; Trudeau, L.E. The role of neurotensin in central nervous system pathophysiology: What is the evidence? J. Psychiatry. Neurosci., 2006, 31, 229-245. (Pubitemid 44085829)
52. Sarret, P.; Esdaile, M.J.; Perron, A.; Martinez, J.; Stroh, T.; Beaudet, A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J. Neurosci., 2005; 25(36), 8188-8196. (Pubitemid 41292113)
53. Labbe-Jullie, S.; Deschaintres, C.; Gully, D.; Le Fur, G.; Kitabgi, P. Effect of the nonpeptide neurotensin antagonist SR 48692 and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ilei.un and colon. J. Pharmacol. Exp. Ther., 1994, 271, 267-276. (Pubitemid 24333139)
54. Gully, D.B.; Labeeuw, R.; Boigegrain, F.; Oury-Donat, A.; Bachy, M.; Poncelet, P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 1997, 280, 802-812.
55. Dubuc, P.; Sarret, C.; Labbe-Jullie, J.M.; Botto, E.; Honore, E.; Bourdel, J.; Martinez, J.; Costentin, J.P.; Vincent, P.; Kitabgi, P.; Mazella, J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci., 1999, 19, 503-510. (Pubitemid 29028989)
56. Yamauchi, R.; Sonoda, S.; Jinsmaa, Y.; Yoshikawa, M. Antinociception induced by beta-lactotensin, a neurotensin agonist peptide derived from betalactoglobulin, is mediated by NT(2) and D(1) receptors. Life Sci., 2003, 73, 1917-1923. (Pubitemid 36934506)
57. Roussy, G.; Baudisson, S.; Ezzoubaa, F.; Belleville, K.; Beaudet, N.; Martinez, J.; Richelson, E.; Sarret, P. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity. Mol. Pain, 2009, 5, 38-42.
58. Maes, V.; Garcia-Garayoa, E.; Bläuenstein, P.; Tourwé, D. Novel 99mTclabeled neurotensin analogues with optimized biodistribution properties. J. Med. Chem., 2006, 49(5), 1833-6. (Pubitemid 43376527)
59. Hughes, F.M. Jr.; Shaner, B.E.; May, L.A.; Zotian, L.; Brower, J.O.; Woods, R.J.; Cash, M.; Morrow, D.; Massa, F.; Mazella, J.; Dix, T.A. Identification and Functional Characterization of a Stable, Centrally Active Derivative of the Neurotensin (8-13) Fragment as a Potential First-in-Class Analgesic J. Med. Chem., 2010, 53, 4623-4632.
60. Gilbert, J.A.; Moses, C.J.; Pfenning, M.A.; Richelson, E. Neurotensin and its analogs-correlation of specific binding with stimulation of cyclic GMP formation in neuroblastoma clone N1E-115. Biochem. Pharmacol., 1986, 35, 391-397. (Pubitemid 16139460)
61. Machida, R.; Tokumura, T.; Tsuchiya, Y.; Sasaki, A.; Abe, K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats. Biol. Pharm. Bull., 1993, 16(1), 43-7. (Pubitemid 23121747)
62. Tyler-McMahon, B.M.; Boules, M.; Richelson, E. Neurotensin: Peptide for the next millennium. Regulatory Peptides, 2000, 93, 125-136.
63. Van Kemmel, F.M.; Dubuc, I.; Bourdel, E. A C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluidbrain barrier in mice. Neurosci. Lett., 1996, 217, 58-60. (Pubitemid 26342793)
64. Zhang, L.; Lee, H.K.; Pruess, T.H.; White, H.S.; Bulaj, G. Synthesis and applications of polyamine amino acid residues: Improving the bioactivity of an analgesic neuropeptide, neurotensin. J Med. Chem., 2009, 52(6), 1514-7.
65. Gully, D.M.; Canton, R.; Boigegrain, F.; Jeanjean, J.C.; Molimard, M.; Poncelet, P. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci., 1993, 90(1), 65-69.
66. Labbé-Jullié, C.; Botto, J.M.; Mas, M.V.; Chabry, J.; Mazella, J.; Vincent, J.P.; Gully, D.; Maffrand, J.P.; Kitabgi, P. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol. Pharmacol., 1995, 47(5), 1050-6.
67. Rostene, W.H.; Alexander, M.J.; Neurotensin and neuroendocrine regulation. Front. Neuroendocrinol., 1997, 18, 115-173. (Pubitemid 27172845)
68. Nisato, D.; Guiraudou, P.; Barthelemy, G.; Gully, D.; Le Fur, G. SR 48692, a non-peptide neurotensin receptor antagonist, blocks the cardiovascular effects elicited by neurotensin in guinea pigs. Life Sci., 1994, 54, 95-100.
69. Azzi, M.; Gully, D.; Heaulme, M.; Bérod, A.; Pélaprat, D.; Kitabgi, P.; Boigegrain, R.; Maffrand, J.P.; LeFur, G.; Rostène, W. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists. Eur. J. Pharmacol., 1994, 255(1-3), 167-74. (Pubitemid 24105757)
70. Dubuc, I.; Costentin, J.; Terranova, J.P.; Barnouin, M.C.; Soubrie, P.; Le Fur, G.; Rostene, W.; Kitabgi, P. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Phramacol., 1994, 112, 352-354. (Pubitemid 24172867)
71. Bentacur, C.; Canton, M. Characterization of a new neurotensin receptor antagonist, SR 142948A, in rat brain. Eur. J. Pharmacol., 1998, 343, 67-77. (Pubitemid 28161053)
72. Pettibone, D.J.; Hess, J.F.; Hey, P.J.; Jacobson, M.A.; Leviten, M.; Lis, E.V.; Mallorga, P.J.; Pascarella, D.M.; Snyder, M.A.; Williams, J.B.; Zeng, Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther., 2002, 300(1), 305-13. (Pubitemid 34028541)
73. Roussy, G.; Beaudry, H.; Lafrance, M.; Belleville, K.; Beaudet, N.; Wada, K.; Gendron, L.; Sarret, P. Altered morphine-induced analgesia in neurotensin type 1 receptor null mice. Neuroscience, 2010, 170(4), 1286-94.
74. Mechanic, J.A.; Sutton, J.E.; Berson, A.E.; Wu, X.; Kwan, J.; Schreiber, R.; Pang, Z.; Button, D.C. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice. Eur. Neuropsychopharmacol., 2009, 19(7), 466-75.
75. Kinkead, B.; Dobner, P.R.; Egnatashvili, V.; Murray, T.; Deitemeyer, N.; Nemeroff, C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: Restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther., 2005, 305, 256-64. (Pubitemid 41380519)
76. Feifel, D.; Pang, Z.; Shilling, P.D.; Melendez, G.; Schreiber, R.; Button, D. Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity. Behav. Brain Res., 2010, 212(2), 174-8.
77. Oliveros, A.; Heckman, M.G.; Del Pilar Corena-McLeod, M.; Williams, K.; Boules, M.; Richelson, E. Sensorimotor gating in NTS1 and NTS2 null mice: Effects of d-amphetamine, dizocilpine, clozapine and NT69L. J. Exp. Biol., 2010, 213(24), 4232-9.
78. Kim, E.R.; Leckstrom, A.; Mizuno, T.M. Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice. Behav. Brain Res., 2008, 194(1), 66-71.
79. Lee ,M.R.; Hinton, D.J.; Unal, S.S.; Richelson, E.; Choi, D.S. Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2. Alcohol Clin. Exp. Res., 2011, 35(1), 99-107.
80. Yamauchi, R.; Wada, E.; Kamichi, S.; Yamada, D.; Maeno, H.; Delawary, M.; Nakazawa, T.; Yamamoto, T.; Wada, K. Neurotensin type 2 receptor is involved in fear memory in mice. J. Neurochem., 2007, 102(5), 1669-76. (Pubitemid 47256210)
81. Cáceda, R.; Kinkead, B.; Nemeroff, C.B. Neurotensin: Role in psychiatric and neurological diseases. Peptides, 2006, 27(10), 2385-404. (Pubitemid 44402784)
82. Weinberger, D.R.; Lipska, B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground. Schizophr. Res., 1995, 16(2), 87-110.
83. Bachus, S.E.; Kleinman, J.E. The neuropathology of schizophrenia. J. Clin. Psychiatry., 1996, 57 Suppl 11, 72-83. (Pubitemid 26389789)
84. Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia, Neuron, 2003, 40, 881-884. (Pubitemid 37522046)
85. Lewis, D.A.; Hashimoto, T.; Volk, D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci., 2005, 6, 312-324. (Pubitemid 40469985)
86. Drew, K.L.; O'Connor, W.T.; Kehr, J.; Ungerstedt, U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol., 1990, 187(3), 385-97. (Pubitemid 20357490)
87. Ferré, S.; Schwarcz, R.; Li, X.M.; Snaprud, P.; Ogren, S.O.; Fuxe, K. Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Psychopharmacology, 1994, 116(3), 279-84. (Pubitemid 24345277)
88. Osborne, P.G.; O'Connor, W.T.; Beck, O.; Ungerstedt, U. Acute versus chronic haloperidol: Relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain. Res., 1994, 634(1), 20-30. (Pubitemid 24013542)
89. O'Connor, W.T. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J. Neurosci. Methods., 2001, 109(1):31-9. (Pubitemid 32727885)
90. O'Donnell, P.; Grace, A.A. Dysfunctions in multiple interrelate systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr. Bull., 1998, 24(2), 267-83. (Pubitemid 28404985)
91. Nestler, E.J.; Carlezon, W.A. Jr. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry, 2006, 59, 1151-1159. (Pubitemid 44192421)
92. Reid, M.S.; O'Connor, W.T.; Herrera-Marschitz, M.; Ungerstedt, U. The effect of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: Evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 type receptors. Brain Res., 1990, 519, 255-260. (Pubitemid 20199696)
93. Ferré, S.; O'Connor, W.T.; Fuxe, K.; Ungerstedt, U. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J. Neurosci., 1993, 13(12), 5402-6. (Pubitemid 24001022)
94. Carlsson, A.; Waters, N.; Carlsson, M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry, 1999, 46(10):1388-95.
95. Centonze, D.; Picconi, B.; Baunez, C.; Borrelli, E.; Pisani, A.; Bernardi, G.; Calabresi, P. Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology, 2002, 26, 164-175. (Pubitemid 34093079)
96. Bourdelais, A.; Kalivas, P.W. Amphetamine lowers extracellular GABA concentration in the ventral pallidum. Brain. Res., 1990, 16, 132-136. (Pubitemid 20189210)
97. Linderfors, N.; Hurd, Y.L.; O'Connor, W.T.; Brene, S.; Persson, H.; Ungerstedt, U. Amphetamine regulation of acetylcholine and gammaaminobutyric acid in nucleus accumbens. Neuroscience, 1992 48 439-448.
98. Bissette, G.; Nemeroff, C.B.; Loosen, P.T.; Prange, A.J., Lipton, M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature, 1976, 262, 607-609.
99. Clineschmidt, B.V.; McGuffin, J.C. Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli, Eur. J. Pharmacol., 1977, 46, 395-396. (Pubitemid 8240495)
100. Quirion, R. Interactions between neurotensin and dopamine in the brain: An overview. Peptides, 1983, 4(5), 609-15. (Pubitemid 14223700)
101. Kasckow, J.; Nemeroff, C.B. The neurobiology of neurotensin: Focus on neurotensin dopamine interactions. Regul. Pept., 1991, 36, 153-164.
102. Lambert, P.D.; Gross, R.; Nemeroff, C.B.; Kilts, C.D. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann. N. Y. Acad. Sci., 1995, 757, 377-89.
103. Garver, D.L.; Bissette, G.; Yao, J.K.; Nemeroff, C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry, 1991, 148, 484-488.
104. Rostene W.; Brouard, A.; Dana, C.; Masuo, Y.; Agid, F.; Vial, M.; Lhiaubet, A.M.; Pelaprat, D. Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence. Ann. N.Y. Acad. Sci., 1992, 668, 217-231. (Pubitemid 23025859)
105. Fernandez, A.; de Ceballos, M.L.; Jenner, P.; Marsden, C.D. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience, 1994, 61, 73-79. (Pubitemid 24199512)
106. Kinkead, B.; Nemeroff, C.B. Neurotensin: An endogenous antipsychotic? Curr. Opin. Pharmacol., 2002, 2, 99-103.
107. Nemeroff, C.B. Neurotensin: Perchance an endogenous neuroleptic? Biol. Psychiatry, 1980, 15(2), 283-302. (Pubitemid 10130688)
108. Kinkead, B.; Nemeroff, C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int. Rev. Neurobiol., 2004, 59, 327-49. (Pubitemid 39752420)
109. Da-Silva, S.L.; Brandäo, M.L.; Tomaz, C. Behavioral effects of neurotensin applied to periventricular structures of rats. Braz. J. Med. Biol. Res., 1989, 22(6), 711-715. (Pubitemid 19156166)
110. Shandra, O.A.; Hodlevskyǐ, L.S.; Panenko, A.V.; Vastíanov, R.S.; Oliǐnyk, A.A. Effect of intracerebral administration of somatostatin and neurotensin on posture and movement disorders. Fiziol. Zh., 1994, 40(1), 71-7.
111. Jolicoeur, F.B.; Gagne, M.A.; Rivest, R.; Drumheller, A.; St-Pierre, S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull., 1993, 32, 487-491. (Pubitemid 23251952)
112. Kilts, C.D.; Anderson, C.M.; Bissette, G.; Ely, T.D.; Nemeroff, C.B. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem. Pharmacol., 1988, 37(8), 1547-54. (Pubitemid 18093349)
113. Merchant, K.M.; Dobner, P.R.; Dorsa, D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci., 1992, 12, 652-63.
114. Huang, W.; Hanson, G.R. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems. Eur. J. Pharmacol., 1997, 332(1), 15-21. (Pubitemid 27346599)
115. Radke, J.M.; Owens, M.J.; Ritchie, J.C. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc. Natl. Acad. Sci., 1998, 95, 1146-1150.
116. Kinkead, B.; Shahid, S.; Owens, M.J.; Nemeroff, C.B. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. J. Pharmacol. Exp. Ther., 2000, 295(1), 67-73.
117. Shi, W.X.; Bunney, B.S. Actions of neurotensin: A review of the electrophysiological studies.Ann. N. Y. Acad. Sci., 1992, 668,129-45. (Pubitemid 23025852)
118. Kalivas, P.W.; Miller, J.S. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. Brain Res., 1984, 300, 157-160. (Pubitemid 14104104)
119. Fuxe, K.; O'Connor, W.T.; Antonelli, T.; Osborne, P.G.; Tanganelli, S.; Agnati, L.F.; Ungerstedt, U. Evidence for a substrate of neuronal plasticity based on pre-and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci., 1992, 89, 5591-5595.
120. Nemeroff, C.B.; Bissette, G.; Manberg, P.J.; Osbahr, A.J.; Breese G.R.; Prange, A.J. Neurotensin-induced hypothermia: Evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroid axis. Brain Research, 1980, 195(1), 69-84. (Pubitemid 10077831)
121. Breslin, N.A.; Suddath. R.L.; Bissette, G. CSF concentrations of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates. Schizophr. Res., 1994, 12, 35-41. (Pubitemid 24135493)
122. Sharma, R.P.; Janicak, P.G.; Bissette, G. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 1997, 154, 1019-1021. (Pubitemid 27274549)
123. Myers, B.; Levant, B.; Bissette, G.; Nemeroff, C.B. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment, Brain Res., 1992 575, 325-328.
124. Kitabgi, P.; Hervé, D.; Studler, J.M.; Tramu, G.; Rostène, W.; Tassin, J.P. Neurotensin/dopamine interactions. Encephale, 1989, spec No 91-4.
125. Deutch, A.Y.; Zahm, D.S. The current status of neurotensin-dopamine interactions. Issues and speculations. Ann. N.Y. Acad. Sci., 1992, 668, 232-252. (Pubitemid 23025860)
126. Agnati, L.F.; Fuxe, K.; Benfenati, F.; Battistini, N. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H- Npropylnorapomorphine binding sites. Acta Physiol. Scand., 1983, 119, 459-461. (Pubitemid 14214775)
127. von Euler G.; Fuxe, K. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand., 1987, 131, 625-626. (Pubitemid 18066335)
128. Tanganelli, S.; Li, X.M.; Ferraro, L.; von Euler, G.; O'Connor, W.T.; Bianchi, C.; Beani, L.; Fuxe, K. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Eur. J. Pharmacol., 1993, 230, 159-166. (Pubitemid 23024998)
129. Li, X.M.; Ferraro, L.; Tanganelli, S.; O'Connor, W.T.; Hasselrot, U.; Ungerstedt, U.; Fuxe, K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: A receptor binding and microdialysis study. J. Neural Transm.: Gen. Sect., 1995, 102, 125-137.
130. Li, X.M.; Von Euler, G.; Hedlund, P.B.; Finnman, U.B.; Fuxe, K. The Cterminal neurotensin-(8-13) fragment potently modulates rat neostriatal dopamine D2 receptors. Eur. J. Pharmacol., 1993, 234, 125-128. (Pubitemid 23093415)
131. von Euler, G.; van der Ploeg, I.; Fredholm, B.B.; Fuxe, K. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G proteinindependent mechanism. J. Neurochem., 1991, 56, 178-183. (Pubitemid 21901946)
132. Fuxe, K.; Li, X.M.; Tanganelli, S.; Hedlund, P.; O'Connor, W.T.; Ferraro, L.; Ungerstedt, U.; Agnati, L.F. Receptor-receptor interactions and their relevance for receptor diversity. Focus on neuropeptide/dopamine interactions. Ann. N.Y. Acad. Sci., 1995, 757, 365-376.
133. von Euler, G.; Mailleux, P.; Vanderhaeghen, J.J.; Fuxe, K. Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen. Neurosci. Lett., 1990, 109, 325-330. (Pubitemid 20056978)
134. Tanganelli, S.; O'Connor, W.T.; Ferraro, L.; Bianchi, C.; Beani, L.; Ungerstedt, U.; Fuxe, K. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience, 1994, 60, 649-657.
135. Pickel V.M.; Chan, J.; Delle Donne, K.T.; Boudin, H.; Pelaprat, D.; Rostène, W. High-affinity neurotensin receptors in the rat nucleus accumbens: Subcellular targeting and relation to endogenous ligand. J. Comp. Neurol., 2001, 435, 142-155. (Pubitemid 32480004)
136. Sanz, B.; Exposito, I.; Mora, F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport, 1993, 4, 1194-1196. (Pubitemid 23278564)
137. Saleh, T.M.; Kombian, S.B.; Zidichouski, J.A.; Pittman, Q.J. Cholecystokinin and neurotensin inversely modulate excitatory synaptic transmission in the parabrachial nucleus in vitro. Neuroscience, 1997, 77, 23-35. (Pubitemid 27060303)
138. Ferraro, L.; Antonelli, T.; O'Connor, W.T.; Fuxe, K.; Soubrié, P.; Tanganelli, S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: Functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J. Neurosci., 1998, 18, 6977-6989. (Pubitemid 28388026)
139. Ferraro, L.; Tomasini, M.C.; Siniscalchi, A.; Fuxe, K.; Tanganelli, S.; Antonelli, T. Neurotensin increases endogenous glutamate release in rat cortical slices. Life Sci., 2000, 66(10), 927-936. (Pubitemid 30084479)
140. Ferraro, L.; Tomasini, M.C.; Fernandez, M.; Bebe, B.W.; O'Connor, W.T.; Fuxe, K.; Glennon, J.C.; Tanganelli, S.; Antonelli, T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: A dual-probe microdialysis study in intact conscious rat brain. Neuroscience, 2001, 102, 113-120. (Pubitemid 32171857)
141. Matsuyama, S.; Fukui, R.; Higashi, H.; Nishi, A. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: Involvement of glutamate signalling. Eur. J. Neurosci., 2003, 18, 1247-1253. (Pubitemid 37115043)
142. Chen, L.; Yung, K.K.; Yung, W.H. Neurotensin selectively facilitates glutamatergic transmission in globus pallidus. Neuroscience, 2006, 141, 1871-1878. (Pubitemid 44233153)
143. Shenton, M.E.; Dickey, C.C.; Frumin, M.; McCarley, R.W. A review of MRI findings in schizophrenia. Schizophr. Res., 2001, 49(1-2), 1-52. (Pubitemid 32451739)
144. Gruber, S.H.; Angelucci, F.; Nomikos, G.G.; Mathé, A.A. Effects of olanzapine on extracellular concentrations and tissue content of neurotensin in rat brain regions. Eur Neuropsychopharmacol. 2011 (in press).
145. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry, 1991, 148(11), 1474-86.
146. Petkova-Kirova, P.; Rakovska, A.; Zaekova, G.; Ballini, C.; Corte, L.D.; Radomirov, R.; Vágvölgyi, A. Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: Possible role of NTR1 receptors in neuropsychiatric disorders. Neurochem Int., 2008, 53(6-8), 355-61.
147. Kuroki, T.; Meltzer, H.Y.; Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther., 1999, 288(2), 774-81. (Pubitemid 29119694)
148. Ichikawa, J.; Kuroki, T.; Dai, J.; Meltzer, H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol., 1998, 351(2), 163-71. (Pubitemid 28312927)
149. Merchant, K.M.; Dobie, D.J.; Filloux, F.M.; Totzke, M.; Aravagiri, M.; Dorsa, D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J.Pharmacol. Exp. Ther., 1994, 271(1), 460-71. (Pubitemid 24333164)
150. Fadel, J.; Dobner, P.R.; Deutch, A.Y. Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice. Neurosci. Lett., 2006, 402(1-2), 97-101. (Pubitemid 43766450)
151. Shilling, P.D.; Richelson, E.; Feifel, D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res., 2003, 143(1), 7-14. (Pubitemid 36802179)
152. Ferraro, L.; Beggiato, S.; Tomasini, M.C.; Fuxe, K.; Tanganelli, S.; Antonelli, T. Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: An in vivo microdialysis study. J. Neurosci. Res., 2011.
153. Ferraro, L.; Tomasini, M.C.; Beggiato, S.; Guerrini, R.; Salvadori, S.; Fuxe, K.; Calzà, L.; Tanganelli, S.; Antonelli, T. Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev. Med. Chem., 2009, 9(12), 1429-38.
154. Li, Z.; Boules, M.; Williams, K.; Peris, J.; Richelson, E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res., 2010, 1311, 28-36.
155. Antonelli, T.; Tomasini, M.C.; Finetti, S.; Giardino, L.; Calzà, L.; Fuxe, K.; Soubriè, P.; Tanganelli, S.; Ferraro, L. Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture. J. Neurosci. Res., 2002, 70(6), 766-73. (Pubitemid 35416893)
156. Antonelli, T.; Ferraro, L.; Fuxe, K.; Finetti, S.; Fournier, J.; Tanganelli, S.; De Mattei, M.; Tomasini, M.C. Neurotensin enhances endogenous extracellular glutamate levels in primary cultures of rat cortical neurons: Involvement of neurotensin receptor in NMDA induced excitotoxicity. Cereb. Cortex., 2004, 14(4), 466-73. (Pubitemid 38506977)
157. Ferraro, L.; Tomasini, M.C.; Mazza, R.; Fuxe, K.; Fournier, J.; Tanganelli, S.; Antonelli, T. Neurotensin receptors as modulators of glutamatergic transmission. Brain Res. Rev., 2008, 58(2),365-73.
158. Allen, G.V.; Cheung, R.T.; Cechetto, D.F. Neurochemical changes following occlusion of the middle cerebral artery in rats. Neuroscience, 1995, 68(4),1037-50.
159. Cheung, R.T.; Cechetto, D.F. Neuropeptide changes following excitotoxic lesion of the insular cortex in rats. J. Comp. Neurol., 1995, 362(4), 535-50
160. Liu, J.; Zhao, J.; Di, Y.F.; Guo, X.X.; Zhai, G.R.; Huang, X.H. The dynamic changes of plasma neuropeptide y and neurotensin and their role in regulating cerebral hemodynamics in neonatal hypoxic-ischemic encephalopathy. Am. J. Perinatol., 2007, 24(7), 435-40. (Pubitemid 47254982)
161. Mueller, A.L.; Artman, L.D.; Balandrin, M.F.; Brady, E.; Chien, Y.; Delmar, E.G.; George, K.; Kierstead, A.; Marriott, T.B.; Moe, S.T.; Newman, M.K.; Raszkiewicz, J.L.; Sanguinetti, E.L.; van Wagenen, B.C.; Wells, D. NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann. N. Y. Acad. Sci., 1999, 890, 450-7. (Pubitemid 30040406)
162. Culmsee, C.; Junker, V.; Kremers, W.; Thal, S.; Plesnila, N.; Krieglstein, J. Combination therapy in ischemic stroke: Synergistic neuroprotective effects of memantine and clenbuterol. Stroke, 2004, 35(5),1197-202 (Pubitemid 38543543)
163. Antonelli, T.; Tomasini, M.C.; Fournier, J.; Mazza, R.; Tanganelli, S.; Pirondi, S.; Fuxe, K.; Luca, F. Neurotensin receptor involvement in the rise of extracellular glutamate levels and apoptotic nerve cell death in primary cortical cultures after oxygen and glucose deprivation. Cereb. Cortex., 2008, 18(8),1748-57. (Pubitemid 352019911)
164. Babcock, A.M.; Baker, D.A.; Hallock, N.L.; Lovec, R.; Lynch, W.C.; Peccia, J.C. Neurotensin-induced hypothermia prevents hippocampal neuronal damage and increased locomotor activity in ischemic gerbils. Brain Res. Bull., 1993, 32(4), 373-8. (Pubitemid 23242825)
165. Torup, L.; Borsdal, J.; Sager, T. Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Neurosci. Lett., 2003, 351(3), 173-6. (Pubitemid 37410332)
166. Dubuc, I.; Costentin, J.; Doulut, S.; Rodriguez, M.; Martinez, J.; Kitabgi, P. JMV 449: A pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur. J. Pharmacol., 1992, 219(2), 327-9.
167. Krieger, D.W.; Yenari, M.A. Therapeutic hypothermia for acute ischemic stroke: What do laboratory studies teach us? Stroke, 2004, 35(6), 1482-9. (Pubitemid 38697480)
168. Gully, D.; Jeanjean, F.; Poncelet, M.; Steinberg, R.; Soubrié, P.; Le Fur, G.; Maffrand, J.P. Neuropharmacological profile of non-peptide neurotensin antagonists. Fundam. Clin. Pharmacol., 1995, 9(6), 513-21. (Pubitemid 26032244)